Theravance Biopharma Inc (TBPH)
9.17
-0.05
(-0.54%)
USD |
NASDAQ |
Apr 24, 16:00
9.165
0.00 (0.00%)
Pre-Market: 20:00
Theravance Biopharma Profit Margin (Quarterly): -48.45% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -48.45% |
| September 30, 2023 | -57.03% |
| June 30, 2023 | -113.8% |
| March 31, 2023 | -212.0% |
| December 31, 2022 | -70.74% |
| September 30, 2022 | |
| June 30, 2022 | -74.13% |
| March 31, 2022 | -196.6% |
| December 31, 2021 | -214.3% |
| September 30, 2021 | -267.6% |
| June 30, 2021 | -405.8% |
| March 31, 2021 | -558.9% |
| December 31, 2020 | -312.0% |
| September 30, 2020 | -403.4% |
| June 30, 2020 | -419.0% |
| March 31, 2020 | -418.2% |
| December 31, 2019 | -222.4% |
| September 30, 2019 | -470.2% |
| June 30, 2019 | -152.3% |
| March 31, 2019 | -1.36K% |
| December 31, 2018 | -318.9% |
| September 30, 2018 | -462.9% |
| Date | Value |
|---|---|
| June 30, 2018 | -173.9% |
| March 31, 2018 | -782.4% |
| December 31, 2017 | -1.93K% |
| September 30, 2017 | -1.56K% |
| June 30, 2017 | -1.89K% |
| March 31, 2017 | -2.12K% |
| December 31, 2016 | -1.18K% |
| September 30, 2016 | -178.0% |
| June 30, 2016 | -863.2% |
| March 31, 2016 | -229.0% |
| December 31, 2015 | -1.15K% |
| September 30, 2015 | -442.3% |
| June 30, 2015 | -667.3% |
| March 31, 2015 | -208.2% |
| December 31, 2014 | -4.49K% |
| September 30, 2014 | -860.1% |
| June 30, 2014 | -1.96K% |
| March 31, 2014 | -6.35K% |
| December 31, 2013 | -25.19K% |
| September 30, 2013 | -171.2K% |
| June 30, 2013 | -779.0K% |
| March 31, 2013 | -146.2K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-558.9%
Minimum
Mar 2021
-48.45%
Maximum
Dec 2023
-256.5%
Average
-218.4%
Median
Profit Margin (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 23.16% |
| Nektar Therapeutics | -176.2% |
| Vanda Pharmaceuticals Inc | -5.30% |
| Fate Therapeutics Inc | -2.63K% |
| FibroGen Inc | -207.2% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -17.79% |
| Return on Assets | -11.56% |
| Return on Invested Capital | -17.79% |
| Operating Margin (Quarterly) | -37.56% |
| Return on Net Operating Assets | -83.47% |